🇺🇸 FDA
Patent

US 11939581

Methods and compositions for targeting PD-L1

granted A61KA61K31/7105A61K45/06

Quick answer

US patent 11939581 (Methods and compositions for targeting PD-L1) held by Aligos Therapeutics, Inc. expires Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Aligos Therapeutics, Inc.
Grant date
Tue Mar 26 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K31/7105, A61K45/06, A61P, A61P31/20